Publications by authors named "Hidekatsu Nakai"

Claim this Profile
L
Long-term progression-free survivors ("super responders") to olaparib maintenance in recurrent ovarian cancer: a multicenter real-world study (KCOG-G2101s).
Naho Fukuda, Tsuyoshi Takashima, Hidekatsu Nakai, Emi Yoshioka, Kimihiko Ito

Int J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility and characteristics of comprehensive genomic profiling tests in patients with gynecologic cancer: a multi-institutional survey in Kinki District, Japan.
Shinichi Terada, Tomohito Tanaka, Yoji Hisamatsu, Masato Kita, Mana Taki, Hidekatsu Nakai

Int J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homologous recombination deficiency: a reliable biomarker or a misleading indicator?
Hisamitsu Takaya, Shiro Takamatsu, Hidekatsu Nakai, Noriomi Matsumura

Expert Rev Mol Diagn· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Declining Prevalence of Human Papillomavirus Co-Infections Among Young Japanese Women With Cervical Cancer and Its Precursors.
Eri Yoshiizumi, Mamiko Onuki, Iwao Kukimoto, Fumiaki Takahashi, Tomoya Matsui, Hidekatsu Nakai

J Med Virol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial Intelligence-Based Histopathological Subtyping of High-Grade Serous Ovarian Cancer.
Akihiko Ueda, Hidekatsu Nakai, Chiho Miyagawa, Tomoyuki Otani, Manabu Yoshida

Am J Pathol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study.
Hiroaki Itamochi, Nobuhiro Takeshima, Junzo Hamanishi, Kosei Hasegawa, Motoki Matsuura, Hidekatsu Nakai

J Gynecol Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.
Daisuke Aoki, Tsutomu Tabata, Satoshi Yanagida, Toshiaki Nakamura, Eiji Kondo, Hidekatsu Nakai

J Gynecol Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021.
Hidekatsu Nakai, Takahiro Higashi, Tamaki Kakuwa, Noriomi Matsumura

Int J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interstitial lung disease caused by niraparib in ovarian cancer patient: a case report and literature review.
Masato Shono, Kosuke Murakami, Mamiko Ohta, Hidekatsu Nakai, Noriomi Matsumura

Jpn J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis.
Shin Nishio, Kenta Murotani, Wataru Yamagami, Shiro Suzuki, Hidekatsu Nakai

Gynecol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics.
Hidekatsu Nakai, Noriomi Matsumura

Expert Opin Pharmacother· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer.
Shiro Takamatsu, Hidekatsu Nakai, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai

JAMA Netw Open· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging.
Chiho Miyagawa, Hidekatsu Nakai, Tomoyuki Otani, Ryusuke Murakami, Shiki Takamura

J Gynecol Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic Utility of Hysteroscopic Biopsy in Cases of Suspected Lobular Endocervical Glandular Hyperplasia and Comparison with Cervical Conization.
Reona Shiro, Yasushi Kotani, Mamiko Ohta, Hanako Sato, Yoko Kashima, Hidekatsu Nakai

Healthcare (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on 'Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer'. (. 2021 Sep 30;13:17588359211049639).
Hidekatsu Nakai, Noriomi Matsumura

Ther Adv Med Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an Algorithm to Differentiate Uterine Sarcoma from Fibroids Using MRI and LDH Levels.
Ayako Suzuki, Aki Kido, Mitsuru Matsuki, Yasushi Kotani, Kosuke Murakami, Hidekatsu Nakai

Diagnostics (Basel)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer.
Hidekatsu Nakai, Noriomi Matsumura

Ann Transl Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Ⅱ. Roles of Bevacizumab in the Treatment of Ovarian Cancer].
Mamiko Ohta, Hidekatsu Nakai, Noriomi Matsumura

Gan To Kagaku Ryoho· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment for Locally Resectable Stage IIIC1 Cervical Cancer: A Retrospective, Single-Institution Study.
Yoko Kashima, Kosuke Murakami, Chiho Miyagawa, Hisamitsu Takaya, Yasushi Kotani, Hidekatsu Nakai

Healthcare (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial.
Mika Mizuno, Kimihiko Ito, Hidekatsu Nakai, Hidenori Kato, Shoji Kamiura

Int J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional differences in human papillomavirus type 52 prevalence among Japanese women with cervical intraepithelial neoplasia†.
Iwao Kukimoto, Mamiko Onuki, Kasumi Yamamoto, Hideaki Yahata, Yoichi Aoki, Hidekatsu Nakai

Jpn J Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian teratoid carcinosarcoma with a mutation: a case report and review of the literature.
Masato Aoki, Hisamitsu Takaya, Tomoyuki Otani, Hidekatsu Nakai, Kosuke Murakami

Int Cancer Conf J· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Pregnancies and Deliveries of Patients Who Underwent Fertility-Preserving Surgery for Early-Stage Epithelial Ovarian Cancer.
Shin Nishio, Takayo Takeno, Takeshi Fukuda, Ayumi Shikama, Hidekatsu Nakai

J Clin Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The roles and limitations of bevacizumab in the treatment of ovarian cancer.
Hidekatsu Nakai, Noriomi Matsumura

Int J Clin Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer.
Masayo Ukita, Junzo Hamanishi, Hiroyuki Yoshitomi, Koji Yamanoi, Shiro Takamatsu, Hidekatsu Nakai

JCI Insight· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis